196 related articles for article (PubMed ID: 32187665)
61. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
62. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α.
Joshi A; Wang H; Jiang G; Douglas W; Chan JS; Korach KS; Ellenson LH
Am J Pathol; 2012 Jun; 180(6):2536-47. PubMed ID: 22503752
[TBL] [Abstract][Full Text] [Related]
63. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias.
Konopka B; Paszko Z; Janiec-Jankowska A; Goluda M
Cancer Lett; 2002 Apr; 178(1):43-51. PubMed ID: 11849740
[TBL] [Abstract][Full Text] [Related]
64. Endometrial intraepithelial neoplasia.
Owings RA; Quick CM
Arch Pathol Lab Med; 2014 Apr; 138(4):484-91. PubMed ID: 24678678
[TBL] [Abstract][Full Text] [Related]
65. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
[TBL] [Abstract][Full Text] [Related]
66. Tumor invasion and metastasis--nature or nurture?
Rosser RJ
Hum Pathol; 2001 Dec; 32(12):1416-7. PubMed ID: 11774182
[No Abstract] [Full Text] [Related]
67. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues.
Mutter GL; Monte NM; Neuberg D; Ferenczy A; Eng C
Cancer Res; 2014 May; 74(10):2796-802. PubMed ID: 24662919
[TBL] [Abstract][Full Text] [Related]
68. Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment.
Ma J; Zhang JK; Yang D; Ma XX
Aging (Albany NY); 2020 Nov; 12(21):22152-22173. PubMed ID: 33159014
[TBL] [Abstract][Full Text] [Related]
69. Expression and clinical significance of ghrelin in endometrial hyperplasia and carcinoma of Egyptian patients.
Younes SF; Aiad H; Kandil M; El Kalashy FS
Ultrastruct Pathol; 2015 May; 39(3):207-13. PubMed ID: 25569277
[TBL] [Abstract][Full Text] [Related]
70. Genetic features of endometrioid-type endometrial carcinoma arising in uterine adenomyosis.
Yoshida H; Asami Y; Kobayashi-Kato M; Tanase Y; Uno M; Ishikawa M; Shiraishi K; Kato T
Virchows Arch; 2022 Jul; 481(1):117-123. PubMed ID: 34791535
[TBL] [Abstract][Full Text] [Related]
71. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
72. Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.
Wang L; Piskorz A; Bosse T; Jimenez-Linan M; Rous B; Gilks CB; Brenton JD; Singh N; Köbel M
Int J Gynecol Pathol; 2022 Jan; 41(1):12-19. PubMed ID: 33720084
[TBL] [Abstract][Full Text] [Related]
73. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
[TBL] [Abstract][Full Text] [Related]
74. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
75. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
Forster MD; Dedes KJ; Sandhu S; Frentzas S; Kristeleit R; Ashworth A; Poole CJ; Weigelt B; Kaye SB; Molife LR
Nat Rev Clin Oncol; 2011 May; 8(5):302-6. PubMed ID: 21468130
[TBL] [Abstract][Full Text] [Related]
76. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse Clinical Outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract][Full Text] [Related]
77. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes.
Bogani G; Tibiletti MG; Ricci MT; Carnevali I; Liberale V; Paolini B; Milione M; Vitellaro M; Murgia F; Chiappa V; Ditto A; Ghezzi F; Raspagliesi F
Int J Gynecol Cancer; 2020 Jan; 30(1):56-61. PubMed ID: 31780564
[TBL] [Abstract][Full Text] [Related]
78. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Campanino MR; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):275-286. PubMed ID: 30511743
[TBL] [Abstract][Full Text] [Related]
79. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
Krakstad C; Birkeland E; Seidel D; Kusonmano K; Petersen K; Mjøs S; Hoivik EA; Wik E; Halle MK; Øyan AM; Kalland KH; Werner HM; Trovik J; Salvesen H
PLoS One; 2012; 7(12):e52795. PubMed ID: 23300780
[TBL] [Abstract][Full Text] [Related]
80. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
